SNRIs

Mechanism: Dual Reuptake Inhibition

SNRIs inhibit presynaptic reuptake transporters for both serotonin (5-HT) and norepinephrine (NE), increasing the availability of both neurotransmitters in the synaptic cleft. This distinguishes them from SSRIs, which act almost exclusively on serotonin. The two neurotransmitter systems are not equally engaged at all doses, however. Venlafaxine is the clearest example of this dose-dependent shift: at lower doses, its serotonergic effect predominates and it behaves much like an SSRI; as the dose rises, norepinephrine reuptake inhibition becomes progressively more prominent. This is why venlafaxine's tolerability and blood-pressure profile change as exposure increases — the drug is not "one mechanism" but a spectrum that shifts with dose. Desvenlafaxine, the active metabolite of venlafaxine, shows more balanced dual activity across its dosing range. Duloxetine, levomilnacipran, and milnacipran are generally considered more consistently balanced dual reuptake inhibitors, though milnacipran in particular has a relatively stronger norepinephrine component even at typical use.

Indications Beyond Depression

The added norepinephrine activity gives SNRIs a therapeutic reach that SSRIs largely lack, particularly in modulating descending pain pathways in the spinal cord. This underlies their approved or well-established use in:

• Generalized anxiety disorder and other anxiety-spectrum conditions (shared with SSRIs)
• Diabetic peripheral neuropathy and other neuropathic pain syndromes
• Fibromyalgia
• Chronic musculoskeletal pain, including chronic low back pain and osteoarthritis pain
• Stress urinary incontinence (most notably associated with duloxetine, which enhances pudendal nerve activity to increase urethral sphincter tone)

Milnacipran, notably, is used specifically for fibromyalgia rather than as a primary depression treatment in some markets. Levomilnacipran, the more potent enantiomer, is approved for major depressive disorder. This pain-and-mood dual utility is the single biggest clinical differentiator between SNRIs and SSRIs, and it's the detail most worth remembering for practice.

Adverse Effects

Common effects overlap with SSRIs because of shared serotonergic activity: nausea, dry mouth, sweating, insomnia, and sexual dysfunction (decreased libido, delayed orgasm). The norepinephrine component adds effects SSRIs rarely cause: dose-related elevations in blood pressure and heart rate, which is why blood pressure monitoring is a routine part of SNRI therapy, especially at higher doses. Duloxetine carries a specific hepatotoxicity risk, and this risk climbs meaningfully with concurrent heavy alcohol use or preexisting liver disease — patients should be counseled accordingly. As with any serotonergic agent, SNRIs carry serotonin syndrome risk, particularly when combined with other serotonergic drugs (MAOIs, other antidepressants, triptans, tramadol, certain supplements). All antidepressants in this class carry the boxed warning regarding increased suicidal thinking and behavior in children, adolescents, and young adults, especially during initial treatment and dose changes.

Discontinuation Syndrome

Venlafaxine has a short half-life relative to other antidepressants, and this makes its discontinuation syndrome notably brisk and often more intense — symptoms like dizziness, "brain zaps," irritability, and flu-like malaise can appear within a day or so of a missed dose or abrupt stop. Desvenlafaxine and duloxetine can also produce discontinuation symptoms but venlafaxine is the class exemplar for how quickly and sharply this occurs. Tapering rather than abrupt cessation is standard practice for the whole class.

Nursing Considerations

Key priorities include monitoring blood pressure at baseline and periodically during treatment (particularly with venlafaxine), assessing for signs of serotonin syndrome when co-administered with other serotonergic agents, screening for suicidal ideation in younger patients, and reinforcing that delayed-release capsule formulations must be swallowed whole — not crushed, chewed, or opened — to preserve the intended release profile and avoid dose-dumping.